Insuman Infusat
Insulin human (rDNA origin) — Solution for injection, 100 IU/ml
Quick Facts About Insuman Infusat
Key Takeaways About Insuman Infusat
- Insulin pump only: Insuman Infusat is specifically designed for continuous subcutaneous insulin infusion (CSII) in external insulin pumps — it is not intended for injection with syringes or pens
- Hypoglycemia risk: Low blood sugar is the most common side effect; always carry fast-acting glucose and monitor blood sugar regularly
- Pump malfunction backup: Always have rapid-acting insulin and syringes available as an emergency backup in case of pump failure, as ketoacidosis can develop rapidly
- Individual dosing: Insulin requirements are highly individual and must be determined by a healthcare professional based on blood glucose monitoring
- Storage matters: Store unopened vials in the refrigerator (2–8°C); once in the pump, use within 2 weeks at room temperature
What Is Insuman Infusat and What Is It Used For?
Insuman Infusat is a neutral human insulin solution (100 IU/ml) produced by recombinant DNA technology, specifically designed for continuous subcutaneous insulin infusion (CSII) via external insulin pumps. It is prescribed for the treatment of diabetes mellitus in patients who require insulin to control their blood glucose levels.
Insuman Infusat belongs to the pharmacological class of fast-acting human insulins (ATC code A10AB01). Unlike insulin analogues such as insulin lispro or insulin aspart, Insuman Infusat contains unmodified human insulin that is identical in amino acid sequence to the insulin naturally produced by the human pancreas. The insulin is manufactured using recombinant DNA technology in Escherichia coli bacteria, ensuring high purity and consistency.
The primary indication for Insuman Infusat is the management of diabetes mellitus in patients who require exogenous insulin. This includes individuals with type 1 diabetes, who produce little or no insulin due to autoimmune destruction of pancreatic beta cells, and patients with type 2 diabetes whose blood glucose cannot be adequately controlled through lifestyle modifications and oral hypoglycemic agents alone. Insulin pump therapy with Insuman Infusat provides a particularly refined approach to glycemic control.
Continuous subcutaneous insulin infusion (CSII) delivers insulin through a small catheter inserted under the skin and connected to a programmable pump. The pump delivers a continuous low dose of insulin throughout the day (basal rate) and allows the patient to administer additional doses before meals (bolus doses). This closely mimics the physiological pattern of insulin secretion by a healthy pancreas, often resulting in improved glycemic control compared with multiple daily injections.
Insuman Infusat has a relatively rapid onset of action, typically beginning within 30 minutes after subcutaneous infusion, with peak activity at approximately 1 to 3 hours. The duration of action is approximately 5 to 7 hours. Because the insulin is delivered continuously through the pump, a stable baseline insulin level is maintained, and bolus doses cover carbohydrate intake at meals.
An insulin pump is a small electronic device worn on the body that delivers insulin through a thin tube (infusion set) placed under the skin. The pump is programmed to deliver small, precise amounts of insulin continuously (basal rate), mimicking how a healthy pancreas works. Before meals, you program the pump to deliver an extra dose (bolus) to cover the carbohydrates you eat. This allows for much more flexible and precise insulin delivery compared with fixed-dose injections.
Who should use Insuman Infusat?
Insuman Infusat is indicated for patients with diabetes who have been assessed by their healthcare provider as suitable candidates for insulin pump therapy. Typical candidates include patients with type 1 diabetes who experience frequent or severe hypoglycemia on multiple daily injection regimens, those with marked dawn phenomenon (early morning blood glucose rises), pregnant women with diabetes requiring tight glycemic control, and individuals who lead variable lifestyles that make fixed injection schedules difficult to maintain.
It is important to note that insulin pump therapy requires a significant commitment to self-management. Patients must be willing and able to perform regular blood glucose monitoring, count carbohydrates, program the pump correctly, and troubleshoot any technical issues. Comprehensive training from a diabetes specialist team is essential before starting pump therapy.
How is Insuman Infusat different from other insulins?
While many insulin preparations are available for diabetes management, Insuman Infusat is specifically formulated for insulin pump use. Its neutral pH formulation is designed to minimize crystallization and catheter occlusion, which are common problems that can interrupt insulin delivery in pump systems. Unlike some buffered insulin solutions that may cause infusion set blockages over time, Insuman Infusat's formulation has been optimized for the unique demands of continuous infusion through narrow-gauge tubing and cannulae.
What Should You Know Before Taking Insuman Infusat?
Before using Insuman Infusat, inform your healthcare provider about all medical conditions, current medications, and any history of allergic reactions to insulin. Never share insulin delivery devices between patients due to infection risk. Special precautions apply during pregnancy, illness, and changes in physical activity.
Contraindications
Insuman Infusat must not be used in the following situations:
- Hypoglycemia: Do not administer insulin when blood glucose levels are already low. Insulin will further lower blood sugar and may cause severe hypoglycemia requiring emergency treatment
- Known hypersensitivity: Do not use if you have a known allergy to insulin human or any of the excipients (inactive ingredients) in the formulation, including metacresol, zinc chloride, or sodium dihydrogen phosphate dihydrate
- Inappropriate pump use: Do not use Insuman Infusat for intravenous injection; it is designed exclusively for subcutaneous infusion via an insulin pump
Warnings and Precautions
Several important warnings and precautions should be carefully considered before and during treatment with Insuman Infusat:
Hypoglycemia is the most frequent adverse effect of insulin therapy. Episodes of severe hypoglycemia, if untreated, can cause seizures, loss of consciousness, brain damage, and in extreme cases, death. Patients should be educated about recognizing early symptoms of hypoglycemia (sweating, trembling, hunger, rapid heartbeat, confusion) and carry fast-acting glucose at all times. Patients with long-standing diabetes may develop hypoglycemia unawareness, where the warning symptoms become blunted, making them particularly vulnerable to severe episodes.
Pump malfunction is a critical concern. Any interruption to insulin delivery — whether from catheter occlusion, pump failure, battery depletion, or an empty reservoir — can lead to rapid rise in blood glucose levels and, in patients with type 1 diabetes, the development of diabetic ketoacidosis (DKA) within hours. Patients must always carry backup supplies including rapid-acting insulin, syringes or pen devices, blood glucose monitoring equipment, and ketone testing strips.
Infection at the infusion site is a risk associated with pump therapy. The infusion set should be changed every 48 to 72 hours (as recommended by the pump manufacturer), and the insertion site should be rotated to minimize the risk of lipodystrophy (abnormal fat distribution under the skin) and infection.
Dose adjustment may be necessary in the following circumstances:
- Changes in diet or meal patterns (especially carbohydrate intake)
- Increased or decreased physical activity
- Intercurrent illness, especially infections with fever
- Emotional stress or psychological changes
- Changes in kidney or liver function
- Starting, stopping, or changing doses of other medications
- Switching between different insulin types or brands
- Travel across time zones
Insulin pump reservoirs, infusion sets, and any components that come into contact with insulin or body fluids must never be shared between patients, even if the needle or cannula is changed. Sharing delivery devices carries a serious risk of transmission of blood-borne infections including hepatitis B, hepatitis C, and HIV.
Pregnancy and Breastfeeding
Insulin is the treatment of choice for diabetes during pregnancy. Insuman Infusat may be used during pregnancy if clinically indicated. However, insulin requirements typically change substantially during pregnancy: they often decrease during the first trimester and then increase during the second and third trimesters. After delivery, insulin requirements usually fall rapidly back toward pre-pregnancy levels. Close monitoring of blood glucose is essential throughout pregnancy and the postpartum period.
Insulin does not pass into breast milk in clinically significant amounts and is degraded in the infant's gastrointestinal tract. Therefore, Insuman Infusat can be used safely during breastfeeding. However, lactating women may require adjustments to their insulin dose and diet to maintain optimal glycemic control.
Children and Adolescents
Insulin pump therapy with Insuman Infusat can be used in children and adolescents with diabetes, provided they receive appropriate training and supervision. Pediatric insulin requirements may differ from adult requirements, and the dose must be carefully individualized under the guidance of a pediatric endocrinologist. Parents, caregivers, and school personnel should be trained in pump management and emergency treatment of hypoglycemia.
Elderly Patients
Elderly patients may have reduced renal function, which can slow insulin clearance and increase the risk of hypoglycemia. Insulin dose requirements may be lower in older adults. Additionally, some elderly patients may have difficulty managing the technical aspects of insulin pump therapy, and careful assessment of manual dexterity, cognitive function, and visual acuity should be performed before initiating CSII therapy.
How Does Insuman Infusat Interact with Other Drugs?
Many medications can affect blood glucose levels and may require dose adjustment of Insuman Infusat. Some drugs increase the blood glucose-lowering effect of insulin (increasing hypoglycemia risk), while others decrease it (potentially raising blood glucose). Always inform your healthcare provider about all medications you are taking.
Drug interactions with insulin can be broadly categorized into those that increase the hypoglycemic effect (raising the risk of low blood sugar) and those that decrease the hypoglycemic effect (potentially causing blood glucose to rise). Some medications have variable or unpredictable effects on insulin sensitivity. Understanding these interactions is critical for maintaining safe and effective glycemic control.
Major Interactions
The following medications have clinically significant interactions with insulin and require careful monitoring and potential dose adjustment:
| Drug / Drug Class | Effect on Blood Glucose | Clinical Significance | Recommendation |
|---|---|---|---|
| Beta-blockers (propranolol, atenolol) | May mask hypoglycemia symptoms | High — can hide warning signs of low blood sugar | More frequent blood glucose monitoring; consider cardioselective beta-blockers |
| Corticosteroids (prednisone, dexamethasone) | Significant increase in blood glucose | High — may cause marked hyperglycemia | Increase insulin dose; monitor closely during initiation and withdrawal |
| ACE inhibitors (enalapril, lisinopril) | May increase insulin sensitivity | Moderate — increased risk of hypoglycemia | Monitor blood glucose when starting or adjusting dose |
| Thiazide diuretics (hydrochlorothiazide) | Decrease insulin sensitivity | Moderate — may raise blood glucose | May need insulin dose increase; monitor potassium levels |
| MAO inhibitors | Enhance insulin action | High — risk of severe hypoglycemia | Close glucose monitoring; may need insulin dose reduction |
| Salicylates (high-dose aspirin) | Increase insulin sensitivity | Moderate at high doses | Monitor blood glucose; low-dose aspirin usually not clinically significant |
Minor Interactions
The following medications may have less predictable but still notable effects on blood glucose control when used with insulin:
- Oral contraceptives and hormone replacement therapy: May decrease insulin sensitivity, potentially requiring modest dose increases
- Thyroid hormones: Changes in thyroid function (hypothyroidism or hyperthyroidism) can alter insulin requirements significantly
- Octreotide and somatostatin analogues: May either increase or decrease insulin requirements depending on the clinical context
- Alcohol: Moderate alcohol intake can enhance the blood glucose-lowering effect of insulin and increase hypoglycemia risk, especially if consumed without food. Heavy alcohol intake can initially raise blood glucose but then lead to delayed, prolonged hypoglycemia
- Fluoroquinolone antibiotics: Cases of dysglycemia (both hypo- and hyperglycemia) have been reported in patients on insulin therapy receiving fluoroquinolones
- Sympathomimetics (epinephrine, salbutamol): May increase blood glucose levels through glycogenolysis and gluconeogenesis
What Is the Correct Dosage of Insuman Infusat?
The dose of Insuman Infusat is highly individual and must be determined by a healthcare professional based on the patient's blood glucose levels, carbohydrate intake, physical activity, and other factors. In CSII, approximately 40–60% of the total daily dose is delivered as a continuous basal rate, with the remainder given as meal-time boluses.
There is no universal “correct” dose of insulin. The total daily insulin requirement varies enormously between individuals and depends on factors such as body weight, insulin sensitivity, diet, exercise levels, stress, concurrent illness, and residual endogenous insulin production. The goal of insulin pump therapy is to achieve and maintain blood glucose levels as close to normal as possible while minimizing the risk of hypoglycemia.
Adults
For most adults with type 1 diabetes, the total daily insulin dose (TDD) typically ranges from 0.4 to 1.0 IU per kilogram of body weight per day. In insulin pump therapy, this is divided into:
Basal Rate (Continuous Infusion)
Approximately 40–60% of the total daily dose is delivered as a continuous basal rate. This provides background insulin to control blood glucose between meals and overnight. The basal rate is typically programmed to vary throughout the day, with higher rates during the early morning hours (to counteract the dawn phenomenon) and lower rates during periods of increased activity.
A typical starting basal rate is 0.5–1.0 IU per hour, adjusted according to blood glucose monitoring results.
Bolus Doses (Meal-Time)
The remaining 40–60% of the total daily dose is given as bolus doses before meals. The bolus dose is calculated based on the insulin-to-carbohydrate ratio (typically 1 IU per 10–15 grams of carbohydrate) and a correction factor to bring elevated blood glucose levels back to target. These ratios are individualized and refined over time through careful blood glucose monitoring.
Children
In children and adolescents, insulin requirements vary with age, pubertal stage, and growth. Prepubertal children often require 0.5–0.7 IU/kg/day, while adolescents during puberty may require 1.0–1.5 IU/kg/day or more due to growth hormone-mediated insulin resistance. Children using insulin pumps should be supervised by a pediatric endocrinology team, and parents/caregivers must be thoroughly trained in pump operation and troubleshooting.
| Patient Group | Typical TDD Range | Basal:Bolus Split | Key Considerations |
|---|---|---|---|
| Adults (Type 1) | 0.4–1.0 IU/kg/day | 40–60% basal : 40–60% bolus | Adjust for activity, illness, stress |
| Adults (Type 2) | 0.5–1.5 IU/kg/day | 50% basal : 50% bolus | May be higher due to insulin resistance |
| Children (prepubertal) | 0.5–0.7 IU/kg/day | 40–50% basal : 50–60% bolus | Requires close supervision; highly variable needs |
| Adolescents | 1.0–1.5 IU/kg/day | 45–55% basal : 45–55% bolus | Higher due to puberty-related insulin resistance |
| Pregnancy | Highly variable | Individualized | Decreases in 1st trimester, increases in 2nd/3rd |
Elderly
In elderly patients, insulin requirements may be lower than in younger adults due to reduced renal clearance, decreased food intake, and age-related changes in insulin sensitivity. Starting doses should be conservative, and blood glucose targets may be somewhat higher than for younger patients to reduce the risk of hypoglycemia, which can be particularly dangerous in the elderly (increasing fall risk, cardiac events). The American Diabetes Association (ADA) recommends a less stringent HbA1c target of <8.0% (or even <8.5%) for older adults with significant comorbidities.
Missed Dose
In the context of insulin pump therapy, a missed bolus dose (before a meal) will typically result in a rise in blood glucose after eating. If you realize you have missed a bolus, check your blood glucose and administer a correction dose if needed, following the correction factor programmed into your pump. Do not simply double the next bolus dose.
If the pump has been disconnected or interrupted for a period of time (for example, during bathing or sports), you may need to administer a bolus to cover the missed basal insulin delivery. Consult your diabetes care team for specific guidance on reconnection protocols.
Overdose
An insulin overdose causes hypoglycemia, which may range from mild (managed by consuming sugar or glucose) to severe (requiring assistance from another person). Symptoms of insulin overdose include:
- Sweating, trembling, cold skin
- Rapid heartbeat, palpitations
- Intense hunger
- Confusion, difficulty concentrating
- Headache, visual disturbances
- In severe cases: seizures, loss of consciousness, coma
Mild to moderate hypoglycemia: Consume 15–20 grams of fast-acting carbohydrate (glucose tablets, fruit juice, sugar-containing soft drink). Recheck blood glucose after 15 minutes and repeat if still low.
Severe hypoglycemia (patient unable to self-treat): Another person should administer glucagon (by injection or nasal spray) and call emergency services immediately. Do not attempt to give food or drink to an unconscious person. Once the patient regains consciousness, give oral carbohydrate to prevent recurrence.
What Are the Side Effects of Insuman Infusat?
The most common side effect of Insuman Infusat is hypoglycemia (low blood sugar). Other possible side effects include injection site reactions, lipodystrophy, allergic reactions, edema, and visual disturbances. Most side effects are manageable with proper dose adjustment and monitoring.
Like all insulin preparations, Insuman Infusat can cause side effects, although not everybody experiences them. The most frequently reported adverse effect is hypoglycemia, which occurs when the insulin dose exceeds the body's current requirement. The frequency and severity of hypoglycemia depend on the insulin dose, the timing of meals, exercise levels, and individual sensitivity to insulin.
Side effects are classified below by frequency according to the standard MedDRA convention used by the European Medicines Agency (EMA):
Very Common (>1 in 10 patients)
- Hypoglycemia — The most frequent adverse effect. Symptoms include sweating, trembling, hunger, palpitations, confusion, dizziness, and in severe cases seizures or loss of consciousness
Common (1 in 10 to 1 in 100 patients)
- Injection/infusion site reactions — Redness, swelling, itching, or pain at the catheter insertion site
- Lipodystrophy — Fat tissue changes (lipoatrophy or lipohypertrophy) at injection sites, often resulting from failure to rotate infusion sites
- Edema — Fluid retention, particularly at the start of insulin therapy or after significant improvement in glycemic control
Uncommon (1 in 100 to 1 in 1,000 patients)
- Allergic skin reactions — Urticaria (hives), rash, or generalized itching
- Visual disturbances — Temporary blurring of vision, usually occurring when blood glucose levels change rapidly (resolves spontaneously)
- Peripheral neuropathy — Acute painful neuropathy may occur with rapid improvement of blood glucose control in patients with previously poor control
Rare (<1 in 1,000 patients)
- Severe allergic reactions (anaphylaxis) — Widespread skin reaction, angioedema, bronchospasm, drop in blood pressure. Requires immediate medical attention
- Insulin antibody formation — Development of antibodies against insulin that may necessitate dose adjustment
- Sodium retention — Insulin can cause sodium retention, which may be clinically significant in patients with heart failure
If you experience persistent or worsening injection site reactions, significant weight gain, recurring hypoglycemia, or any symptoms suggestive of an allergic reaction, contact your healthcare provider promptly. Severe allergic reactions to insulin are rare but constitute a medical emergency.
Lipodystrophy prevention
Lipodystrophy — the abnormal distribution of fat tissue at infusion sites — can be minimized by rotating the infusion site with each set change. Common infusion sites include the abdomen (avoiding the area directly around the navel), the upper buttocks, and the outer thighs. Injecting into areas of lipodystrophy can lead to erratic insulin absorption and unpredictable blood glucose levels.
How Should You Store Insuman Infusat?
Store unopened Insuman Infusat in the refrigerator at 2–8°C (36–46°F). Do not freeze. Once in use in the pump, the insulin may be kept at room temperature (up to 25°C / 77°F) for up to 2 weeks. Replace the pump reservoir every 48 hours.
Proper storage of insulin is essential to maintain its potency and safety. Improperly stored insulin may lose effectiveness, leading to inadequate blood glucose control and potentially dangerous hyperglycemia. The following storage guidelines should be followed carefully:
- Unopened (not yet in use): Store in the refrigerator at 2–8°C (36–46°F). Do not place near the freezer compartment. Do not freeze insulin; frozen insulin must be discarded as freezing destroys insulin's biological activity
- In use (in the pump): Insuman Infusat may be kept at room temperature (up to 25°C / 77°F) for up to 2 weeks. Insulin in the pump reservoir should be replaced every 48 hours to ensure stability and minimize the risk of catheter occlusion
- Protect from light: Store the vial or cartridge in the outer carton to protect from light
- Do not use after the expiry date: Check the expiry date printed on the label and carton. Do not use insulin that has expired
- Visual inspection: Before use, always inspect the insulin solution. It should be clear and colorless. Do not use if the solution appears cloudy, discolored, or contains particles
When traveling, keep insulin in an insulated bag or cool pouch to protect it from extreme temperatures. Never leave insulin in a car (which can become very hot or cold), in checked luggage (cargo holds may freeze), or in direct sunlight. Carry spare insulin supplies and emergency injection equipment in your hand luggage when flying.
What Does Insuman Infusat Contain?
Each milliliter of Insuman Infusat contains 100 IU (3.5 mg) of human insulin produced by recombinant DNA technology in E. coli. Excipients include phenol, zinc chloride, trometamol, poloxamer 171, glycerol, hydrochloric acid, sodium hydroxide, and water for injections.
Understanding the composition of your medication is important, particularly if you have known sensitivities to specific ingredients. Insuman Infusat contains the following:
Active ingredient
The active substance is insulin human, produced by recombinant DNA technology using Escherichia coli (strain K12). Each milliliter contains 100 IU (International Units), equivalent to approximately 3.5 mg of human insulin. This insulin is structurally identical to the insulin produced by a healthy human pancreas, consisting of two polypeptide chains (A-chain: 21 amino acids, B-chain: 30 amino acids) linked by disulfide bonds.
Inactive ingredients (excipients)
The excipients in Insuman Infusat serve important functions in maintaining insulin stability, sterility, and suitability for pump use:
- Phenol — Preservative to maintain sterility of the multi-dose preparation
- Zinc chloride — Stabilizes the insulin hexamer structure, contributing to uniform insulin activity
- Trometamol (tromethamine) — pH buffer to maintain the neutral pH of the solution
- Poloxamer 171 — Surfactant that reduces insulin adsorption to the surfaces of pump components and infusion tubing, helping to maintain consistent insulin delivery
- Glycerol — Isotonicity agent ensuring the solution matches the osmotic pressure of body fluids
- Hydrochloric acid and sodium hydroxide — pH adjustment agents
- Water for injections — Solvent for the solution
The neutral pH formulation with poloxamer 171 is a key distinguishing feature of Insuman Infusat, as it reduces the tendency for insulin aggregation and crystallization in the pump mechanism and infusion tubing, problems that can cause catheter blockage and interruption of insulin delivery.
Frequently Asked Questions About Insuman Infusat
Insuman Infusat is a human insulin solution specifically designed for use in external insulin pumps (continuous subcutaneous insulin infusion or CSII). It is used to treat diabetes mellitus in patients who require insulin therapy, including type 1 diabetes and type 2 diabetes that cannot be adequately controlled with oral medications alone. The pump delivers a continuous basal rate of insulin throughout the day and allows programmable bolus doses before meals for precise glycemic control.
Insuman Infusat is specifically formulated for insulin pump use. Its neutral pH formulation contains poloxamer 171, a surfactant that reduces insulin adsorption to pump components and minimizes the risk of crystallization and catheter occlusion. While many patients now use rapid-acting insulin analogues (lispro, aspart, glulisine) in their pumps, Insuman Infusat provides an option for patients who prefer or require unmodified human insulin rather than an analogue.
If your insulin pump malfunctions, you must switch to manual insulin injections immediately. Always carry rapid-acting insulin and syringes or an insulin pen as backup. Without continuous insulin delivery, blood glucose can rise dangerously fast, and diabetic ketoacidosis (DKA) can develop within hours in type 1 diabetes. Check your blood glucose, test for ketones, and contact your healthcare provider or diabetes specialist nurse promptly. Follow the emergency injection plan that your diabetes team should have established with you.
Yes, hypoglycemia (low blood sugar) is the most common side effect of all insulin preparations, including Insuman Infusat. It occurs when the insulin dose exceeds the body's current requirement, for example due to a missed or delayed meal, increased physical activity, or an incorrect bolus dose. Symptoms include sweating, trembling, hunger, confusion, palpitations, and dizziness. Severe hypoglycemia can cause seizures and loss of consciousness. Always carry fast-acting glucose and ensure that people close to you know how to administer glucagon in an emergency.
Store unopened Insuman Infusat in a refrigerator at 2–8°C (36–46°F). Do not freeze. Once in use in the pump, the insulin can be kept at room temperature (up to 25°C / 77°F) for up to 2 weeks. The pump reservoir should be changed every 48 hours. Always inspect the insulin before use — it should be clear and colorless. Discard any insulin that appears cloudy, discolored, or contains particles. Protect from direct sunlight and excessive heat.
Yes, insulin is the recommended treatment for diabetes during pregnancy, and Insuman Infusat may be used if clinically appropriate. However, insulin requirements change significantly during pregnancy: they typically decrease in the first trimester and increase during the second and third trimesters. After delivery, insulin needs usually drop rapidly. Close blood glucose monitoring and regular adjustment of pump settings are essential throughout pregnancy and the postpartum period. Your obstetrician and diabetes team should work together to optimize your care.
References
All medical information on this page is based on peer-reviewed research and international clinical guidelines. The following sources were used:
- European Medicines Agency (EMA). Insuman Infusat — Summary of Product Characteristics (SmPC). European public assessment report. Available at: www.ema.europa.eu
- American Diabetes Association (ADA). Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1–S321. DOI: 10.2337/dc24-SINT
- Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetologia. 2022;65:1925–1966. DOI: 10.1007/s00125-022-05787-2
- National Institute for Health and Care Excellence (NICE). Type 1 diabetes in adults: diagnosis and management (NG17). Updated 2022. Available at: www.nice.org.uk/guidance/ng17
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Insulin is included as an essential medicine. Available at: www.who.int
- Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med. 2012;366(17):1616–1624. DOI: 10.1056/NEJMct1113948
- Bode BW, et al. Continuous subcutaneous insulin infusion therapy today. Diabetes Metab Res Rev. 2019;35(5):e3141. DOI: 10.1002/dmrr.3141
- International Society for Pediatric and Adolescent Diabetes (ISPAD). Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes. 2022;23(8):1277–1296.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in endocrinology, diabetology, and clinical pharmacology.
Content developed by physicians with specialist qualifications in endocrinology and diabetes management. All clinical claims are supported by Level 1A evidence from systematic reviews, meta-analyses, and international guidelines.
Independently reviewed by the iMedic Medical Review Board. Adherence to international guidelines (WHO, ADA, EASD, NICE) verified. Last review: .
All content follows the GRADE evidence framework. No commercial funding or pharmaceutical sponsorship. Transparent conflict-of-interest declaration. Read our editorial standards.
Medical information is reviewed and updated regularly to reflect the latest clinical evidence and guideline changes. Last fact-check: .